Megan Hollasch

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication OncologyLive, aiding in all aspects of the publication process, as well as content for OncLive.com.

Articles

Notable 2024/Early 2025 Multiple Myeloma NCCN Guideline Updates Feature Quadruplets and More

November 6th 2024

Shaji Kumar, MD, details key updates/revisions made to the multiple myeloma NCCN guidelines in 2024 and the first version of the 2025 guidelines.

Brahmer's Take: Advancements in 3 Cornerstone Settings of NSCLC

November 6th 2024

Julie R. Brahmer, MD, MSc, FASCO, details practice-changing indications and notable data in the early-stage, neo(adjuvant), and metastatic NSCLC settings.

The Top News From ESMO 2024: A Variety of Data Inform Solid Tumor Landscapes

November 1st 2024

This roundup includes exclusive insights from 23 clinicians and key data on the top abstracts coming out of the 2024 ESMO Annual Meeting.

Inavolisib Regimen Approval Opens the Door for Triplet Therapies in HR+, HER2– Breast Cancer

October 31st 2024

Hope Rugo, MD, FASCO, discusses the FDA approval of inavolisib, how it will be incorporated into care, and the patient population evaluated in INAVO120.

Effectively Targeting c-Met in Colorectal Cancer Is Becoming a Reality With Novel Approaches

October 31st 2024

John Strickler, MD, details the latest data on the novel c-Met–targeted ADC telisotuzumab adizutecan and how the agent could affect the treatment of CRC.

Novel HPK1 Inhibitor NDI-101150 Shows Early Activity in RCC

October 29th 2024

Anita Scheuber, MD, PhD, details the mechanism of action of NDI-101150, early data seen with the agent, and next steps in the HPK1 inhibitor’s investigation.

The Debate Over the Predictive Utility of PD-L1–Low Expression is Ongoing in ESCC

October 28th 2024

Nataliya Uboha, MD, PhD, discusses the FDA’s ODAC’s recommendation to restrict anti–PD-1 agents to patients with PD-L1–positive ESCC.

ctDNA Generates Momentum in Adjuvant Stage II/III Colon Cancer Setting

October 28th 2024

John L. Marshall, MD, details updates with ctDNA in colorectal cancer, and how precision medicine with ctDNA could change the way patients are treated.

Frontline Palbociclib Opens the Door to Subsequent CDK4/6 Inhibition in Metastatic Breast Cancer

October 25th 2024

Jairam Krishnamurthy, MD, FACP, discusses the selective use of CDK4/6 inhibitors after prior progression on these agents in patients with breast cancer.

ODAC Votes on PD-1 Inhibitors Underscore Importance of Biomarker Testing in Gastric/GEJ and Esophageal Cancers

October 25th 2024

Nataliya Uboha, MD, PhD, discusses the evolving treatment landscape for patients with gastric, gastroesophageal junction, and esophageal cancers.

INCA033989 May Address Need for Disease-Modifying Therapies in Myelofibrosis

October 25th 2024

Daniel J. DeAngelo MD, PhD, discusses the potential role for INCA033989 as a disease-modifying therapy in CALR type 1–mutated myelofibrosis.

2024 Regulatory Approvals Across NSCLC Propel the Therapeutic Landscape Forward

October 24th 2024

Noman Ashraf, MD, discusses the evolving treatment landscape in non–small cell lung cancer following numerous regulatory approvals in the space.

Adjuvant Ribociclib Revamps HR+/HER2– Breast Cancer Management

October 24th 2024

Jairam Krishnamurthy, MD, FACP, discusses factors that influence his choice between ribociclib and abemaciclib in the adjuvant breast cancer setting.

Telisotuzumab Adizutecan Delivers Early Signals of Antitumor Activity in CRC

October 23rd 2024

John H. Strickler, MD, discusses treatment with telisotuzumab adizutecan for CRC as well as this ADC’s potential to broaden the CRC treatment paradigm.

ADCs Redefine HER2+ NSCLC Landscape With Potential to Shift to the Frontline Setting

October 23rd 2024

Noman Ashraf, MD, discusses data with T-DXd in HER2-mutated and -overexpressing lung cancer populations and next steps with ADC combination therapies.

First-in-Class Bicycle Toxin Conjugate Targeting Nectin-4 Generates Excitement in Urothelial Carcinoma

October 23rd 2024

Oncologists detail how zelenectide pevedotin, which is under evaluation in the Duravelo-2 trial, could fill an unmet need in metastatic urothelial carcinoma.

Telisotuzumab Adizutecan Represents a Novel c-Met–Targeting ADC in MET-Amplified CRC

October 21st 2024

John H. Strickler, MD, highlights the mechanism of action of telisotuzumab adizutecan and the rationale for targeting c-Met in colorectal cancer.

New Global Hematology Journal Strives to Feature Innovative and Adaptable Research

October 21st 2024

Jorge Cortes, MD, inaugural editor-in-chief of Blood Global Hematology, details what type of research the new journal will highlight and its importance.

Asciminib Yields Promising Efficacy vs SOC Agents in CML

October 17th 2024

Jorge Cortes, MD, details how asciminib could affect care for patients with CML, diving into key takeaways from the ASC4FIRST trial.

Chemoimmunotherapy Is at the Forefront of the Perioperative NSCLC Paradigm

October 14th 2024

Combination therapies with neoadjuvant ICIs and chemotherapy followed by an adjuvant ICI are here to stay in resectable non–small cell lung cancer.